Table 2.

Univariate and multivariate analyses for survival

		OS			PFS				DMFS				LRFS
	Uni-		Multi-		Uni-		Multi-		Uni-		Multi-		Uni-		Multi-
	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR
Gender	0.005	0.481			0.082	0.684			0.020	0.429			0.368	0.805
Age	0.773	0.997			0.359	0.991			0.706	0.995			0.661	0.995
ECOG	0.084	0.596			0.153	0.663			0.298	0.655			0.565	0.824
H&E-TILs	0.001	0.417	0.003	0.522	0.001	0.341	0.001	0.420	0.001	0.411	0.047	0.553	< 0.001	0.374	0.001	0.396
Po-prT	0.379	1.117			0.485	0.922			0.575	1.098			0.271	0.861
L-prT	0.013	1.108			0.012	1.098			0.574	1.033			0.003	1.127	0.005	1.126
Dmax-prT	0.148	1.219			0.208	1.172			0.772	0.932			0.052	1.300
Dmax-N	0.001	1.534	0.001	1.420	0.001	1.516	0.001	1.366	0.001	1.702	0.001	1.531	0.018	1.283
cT	0.020	1.228			0.077	1.152			0.184	1.168			0.320	1.095
c N	0.001	1.437			0.006	1.308			0.010	1.443			0.099	1.204
cM	0.580	1.143			0.543	1.146			0.141	1.558			0.778	0.927
cTNM	0.028	1.259			0.140	1.152			0.038	1.342			0.630	1.053
Regimen of CT	0.442	1.174			0.076	1.397			0.821	0.935			0.011	1.680	0.002
Cycles of CT	0.358	0.899			0.750	1.033			0.707	0.943			0.892	0.984
Dose of RT	0.830	0.934			0.348	1.139			0.668	1.223			0.826	0.931
Short term response to CCRT	0.001	2.482	0.001		0.001	1.917	0.001		0.001	1.981	0.001		0.001	1.951	0.001

OS Overall Survival, PFS Progression-free Survival, DMFS Distant Metastasis-free Survival, LRFS Locoregional Recurrence-free survival, ECOG Eastern Cooperative Oncology Group, Po-prT Position of primary tumor, L-prT Length of primary tumor, Dmax-prT Greatest dimension of primary tumor, Dmax-N Greatest dimension of lymph node, CT Chemotherapy, RT Radiotherapy